CEBP  Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reid, M. E.
Right arrow Articles by Marshall, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reid, M. E.
Right arrow Articles by Marshall, J. R.
Cancer Epidemiology Biomarkers & Prevention Vol. 11, 1285-1291, November 2002
© 2002 American Association for Cancer Research

Selenium Supplementation and Lung Cancer Incidence

An Update of the Nutritional Prevention of Cancer Trial1

Mary E. Reid2, Anna J. Duffield-Lillico, Linda Garland, Bruce W. Turnbull, Larry C. Clark3 and James R. Marshall

Roswell Park Cancer Institute, Buffalo, NY 14263 [M. E. R., J. R. M.]; Arizona Cancer Center, University of Arizona, Tucson, AZ 85724 [A. J. D-L., L. G.], School of Operations Research, Ithaca, NY 14850 [B. W. T.]

Interest in the chemopreventive effects of the trace element selenium has spanned the past three decades. Of >100 studies that have investigated the effects of selenium in carcinogen-exposed animals, two-thirds have observed a reduction in tumor incidence and/or preneoplastic endpoints (G. F. Combs and S. B. Combs, The Role of Selenium in Nutrition Chapter 10, pp. 413–462. San Diego, CA: Academic Press, 1986, and B. H. Patterson and O. A. Levander, Cancer Epidemiol. Biomark. Prev., 6: 63–69, 1997). The Nutritional Prevention of Cancer Trial, a randomized clinical trial reported by Clark et al. (L. C. Clark et al., JAMA, 276: 1957–1963, 1996), showed as a secondary end point, a statistically significant decrease in lung cancer incidence with selenium supplementation. The adjusted hazard ratio (HR) was 0.56 [95% confidence interval (CI), 0.31–1.01; P = 0.05]. These results were based on active follow-up of 1312 participants.

This reanalysis used an extended Nutritional Prevention of Cancer Trial participant follow-up through the end of the blinded clinical trial on February 1, 1996. The additional 3 years added 8 cases to the selenium-treated group and 4 cases to the placebo group, and increased follow-up to 7.9 years. The relative risk of 0.70 (95% CI, 0.40–1.21; P = 0.18) is not statistically significant. Whereas the overall adjusted HR is not significant (HR = 0.74; 95% CI, 0.44–1.24; P = 0.26), and the HR for current and former smokers was not significant, the trend is toward a reduction in risk of incident lung cancer with selenium supplementation. In a subgroup analysis there was a nominally significant HR among subjects with baseline plasma selenium in the lowest tertile (HR = 0.42; 95% CI, 0.18–0.96; P = 0.04). The analysis for the middle and highest tertiles of baseline showed HRs of 0.91 and 1.25. The current reanalysis indicates that selenium supplementation did not significantly decrease lung cancer incidence in the full population, but a significant decrease among individuals with low baseline selenium concentrations was observed.




This article has been cited by other articles:


Home page
ChestHome page
J. Gray, J. T. Mao, E. Szabo, M. Kelley, J. Kurie, and G. Bepler
Lung Cancer Chemoprevention: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Chest, September 1, 2007; 132(3_suppl): 56S - 68S.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
S. Stranges, J. R. Marshall, R. Natarajan, R. P. Donahue, M. Trevisan, G. F. Combs, F. P. Cappuccio, A. Ceriello, and M. E. Reid
Effects of Long-Term Selenium Supplementation on the Incidence of Type 2 Diabetes: A Randomized Trial
Ann Intern Med, August 21, 2007; 147(4): 217 - 223.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
T. M. Vogt, R. G. Ziegler, B. H. Patterson, and B. I. Graubard
Racial Differences in Serum Selenium Concentration: Analysis of US Population Data from the Third National Health and Nutrition Examination Survey
Am. J. Epidemiol., August 1, 2007; 166(3): 280 - 288.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
K. El-Bayoumy, A. Das, B. Narayanan, N. Narayanan, E. S. Fiala, D. Desai, C. V. Rao, S. Amin, and R. Sinha
Molecular targets of the chemopreventive agent 1,4-phenylenebis (methylene)-selenocyanate in human non-small cell lung cancer
Carcinogenesis, July 1, 2006; 27(7): 1369 - 1376.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. A. Belinsky
Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer
Carcinogenesis, September 1, 2005; 26(9): 1481 - 1487.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
F. R. Hirsch and S. M. Lippman
Advances in the Biology of Lung Cancer Chemoprevention
J. Clin. Oncol., May 10, 2005; 23(14): 3186 - 3197.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
G. F. Combs Jr
Current Evidence and Research Needs to Support a Health Claim for Selenium and Cancer Prevention
J. Nutr., February 1, 2005; 135(2): 343 - 347.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. R. Taylor and P. Greenwald
Nutritional Interventions in Cancer Prevention
J. Clin. Oncol., January 10, 2005; 23(2): 333 - 345.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M.-B. Yin, Z.-R. Li, S. Cao, F. A. Durrani, R. G. Azrak, C. Frank, and Y. M. Rustum
Enhanced 7-Ethyl-10-hydroxycamptothecin (SN-38) Lethality by Methylselenocysteine Is Associated with Chk2 Phosphorylation at Threonine-68 and Down-Regulation of Cdc6 Expression
Mol. Pharmacol., July 1, 2004; 66(1): 153 - 160.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
H. Zhuo, A. H. Smith, and C. Steinmaus
Selenium and Lung Cancer: A Quantitative Analysis of Heterogeneity in the Current Epidemiological Literature
Cancer Epidemiol. Biomarkers Prev., May 1, 2004; 13(5): 771 - 778.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
G. S. Omenn
Human Lung Cancer Chemoprevention Strategies: Parker B. Francis Lecture
Chest, May 1, 2004; 125(5_suppl): 123S - 127S.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
R. C. Winterhalder, F. R. Hirsch, G. K. Kotantoulas, W. A. Franklin, and P. A. Bunn Jr
Chemoprevention of lung cancer--from biology to clinical reality
Ann. Onc., February 1, 2004; 15(2): 185 - 196.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
W.-Q. Wei, C. C Abnet, Y.-L. Qiao, S. M Dawsey, Z.-W. Dong, X.-D. Sun, J.-H. Fan, E. W Gunter, P. R Taylor, and S. D Mark
Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death
Am. J. Clinical Nutrition, January 1, 2004; 79(1): 80 - 85.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
H. Swede, Y. Dong, M. Reid, J. Marshall, and C. Ip
Cell Cycle Arrest Biomarkers in Human Lung Cancer Cells After Treatment with Selenium in Culture
Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1248 - 1252.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2002 by the American Association for Cancer Research.